In possibly the greatest product development race of this century, Pfizer, Moderna, and Johnson and Johnson (J&J) have emerged victorious. These firms beat out 6
Despite an average vaccination rate of 1.41 million doses per day in the U.S, the pandemic continues to take its toll on the population. In
This past week, a dear family member, an older adult, found that she has COVID-19. After her husband was diagnosed and hospitalized, she got tested
As the world waits for COVID-19 vaccines to become widely available, Amarin experiences a different form of anticipation, one which will see the fate of
Image from Newsday. https://www.newsday.com/opinion/editorial/cure-vaccine-immunity-coronavirus-covid-19-rush-trump-science-1.48679327 With everyone is rushing to return pre-pandemic society, it is becoming clear that a vaccine is the only way to truly
Mergers and acquisitions are a hot topic in the biopharmaceutical industry. With 2019 setting records in terms of deal value and volume for biopharmaceutical M&A,
In a relatively quick ruling, one that Amarin expected to occur in Q4 at the earliest, the U.S Court of Appeals for the Federal Circuit
Time is ticking! Need to optimize the value of a new therapy before generics are available. How can we extend the patent? These are all
In a recent interview with Fox News host Chris Wallace, US President Donald Trump discussed his success taking the Montreal Cognitive Assessment (MoCA). The President
We all know one size never fits all, yet, for the vast majority of medical history, care providers have been using that approach. Fortunately, with
